Varex Imaging Corporation is a leading designer and manufacturer of X-ray imaging components — including X-ray tubes, digital detectors, and image-processing software — sold to medical original equipment manufacturers (OEMs), as well as industrial and security imaging customers. Because the company runs a non-standard fiscal calendar ending in early October, the upcoming report covers the fourth quarter of fiscal year 2026. This print matters because it closes the fiscal year and sets the tone for fiscal 2027. Investors are focused on whether the fast-growing Industrial segment can offset choppier Medical demand, and whether tariff and China-related pressures continue to weigh on gross margins. The results will also provide a first look at how management frames the coming year. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
For the fourth quarter of fiscal 2026, analysts tracked by MarketBeat expect Varex to post adjusted EPS of about $0.33 on revenue of approximately $229.8 million. That compares with non-GAAP EPS of $0.37 and revenue of $228.9 million in the same quarter a year earlier — implying expected EPS contraction of roughly 10.8% alongside essentially flat revenue growth of about 0.4%.
Varex does not typically issue detailed quarterly guidance for the full quarter ahead in the same format, so investors will lean on consensus and management commentary. Historically, the company has been a frequent EPS beater, exceeding consensus in seven of its last eight quarters. In its most recent report (the third quarter of fiscal 2026), Varex posted EPS of $0.31, beating the roughly $0.21 consensus, but revenue of $210.5 million missed the roughly $215.5 million estimate — a reminder that the market watches top-line execution as closely as the bottom line. From what I see, this pattern of beating on EPS while missing on revenue highlights the need to monitor both metrics closely.
Sentiment heading into the print is balanced between optimism about the Industrial segment's momentum and caution over Medical softness and margin headwinds. Varex shares have shown meaningful volatility around recent reports, particularly when results diverge across the two segments or when guidance signals pressure ahead. Management has previously flagged that tariffs are weighing on gross margins by an estimated 100 to 150 basis points, and that geopolitical dynamics between China and ex-China Medical sales remain a source of inconsistency. With customer concentration also high — the top 10 customers represented roughly 52% of fiscal 2025 revenue — investors will scrutinize any commentary on order trends and demand visibility across both segments.
Beyond the headline numbers, investors should watch several forward-looking signals. The first is the trajectory of the Industrial segment, which has posted record quarterly revenue on the strength of security inspection and cargo systems. Sustained orders there would reinforce Varex's diversification story, while any slowdown could reset expectations for the new fiscal year.
Second, margin resilience will be a central theme. Tariff costs, product mix, and the ramp of new manufacturing capacity — including radiographic detector production from the company's facility in India — will all influence gross margin in the quarters ahead. Management's guidance on these items will likely matter as much as the reported figures themselves.
Third, watch the Medical segment, where CT tube demand has been a bright spot but oncology and other modalities have shown unevenness. Finally, balance sheet and cash flow trends deserve attention, given the company's earlier use of cash to retire convertible debt and the resulting decline in its cash position. Together, these factors will shape how the market interprets Varex's momentum entering fiscal 2027.
In my own analysis of names like Varex, I find it helpful to cross-reference earnings data with broader market signals. One resource I turn to regularly is Tickeron’s AI Screener, which allows filtering by technical patterns, fundamentals, and AI-driven signals to identify comparable opportunities or shifts in momentum during earnings season. It provides a structured way to scan for trade ideas without relying solely on manual review.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The 10-day moving average for VREX crossed bearishly below the 50-day moving average on November 10, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 86%.
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on VREX as a result. In 61 of 95 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 64%.
VREX moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VREX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.
The Aroon Indicator for VREX entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +0.54% 3-day Advance, the price is estimated to grow further. Considering data from situations where VREX advanced for three days, in 195 of 310 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.
VREX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. VREX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 84 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.577) is normal, around the industry mean (4.142). P/E Ratio (34.148) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (4.979) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.903) is also within normal values, averaging (40.124).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VREX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a manufactures of X-ray tubes, flat panel detectors, connectors and accessories for imaging as well as workstations and software for computer-aided diagnostics and image processing
Industry MedicalNursingServices